Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: February 2008
-
The biotechnology, chemical, and pharmaceuticals (BCP) technology groups at the U.S. Patent Office will hold their first quarterly customer partnership meeting of the year on March 12, 2008. The proposed schedule and topics for discussion include: Morning Session • Greetings and Overview (9:00 – 9:15 AM): John LeGuyader, Bruce Kisliuk, Christopher Low, Directors, Technology Center…
-
By Donald Zuhn — A report on Forbes.com indicates that Millennium Pharmaceuticals spent $1.28 million last year lobbying Congress and the Department of Commerce on patent reform and biologics legislation. According to the report, Millennium disclosed its lobbying tab for the second half of the year in a filing with the Senate public…
-
By Donald Zuhn — If you have been reading the reports placed by John White and Bob Spar over at the PLI Patent Blog, then you are probably already aware that Judge James C. Cacheris of the District Court for the Eastern District of Virginia did not issue a decision today after hearing…
-
By Sherri Oslick — Late last week, U.S. District Court Judge Mary Pat Thynge (D. Del.) granted leave to Amgen Inc. to amend and supplement its reply to ARIAD Pharmaceuticals Inc.’s counterclaims to include new claims of inequitable conduct. In her order, Judge Thynge noted that Amgen pled affirmative acts of misconduct and…
-
By Kevin E. Noonan — District Court Judge James C. Cacheris of the Eastern District of Virginia is set to hear argument tomorrow morning at 10 a.m. (EST) on cross motions for summary judgment in Tafas/GSK v. Dudas. Judge Cacheris, who enjoined implementation of the U.S. Patent and Trademark Office’s ill-conceived and misguided…
-
Monsanto Prevails Again against Infringing Farmer By Kevin E. Noonan — In recent weeks, Monsanto has prevailed in patent infringement lawsuits involving its patented seeds from various crop species genetically engineered to be resistant to glyphosate herbicides such as Roundup® (also a Monsanto product). The U.S. Supreme Court recently refused to grant certiorari…
-
By Donald Zuhn — Invitrogen Corporation and Agilent Technologies announced today that the California-based biotech companies have settled all three of their pending patent suits. Agilent Technologies became involved in the litigations through its 2007 acquisition of Stratagene, Inc., which was sued by Invitrogen in 2000 and 2001 and which brought suit against…
-
By Donald Zuhn — Last week, Swiss drug maker Novartis AG agree to supply its cancer drug Glivec® at no cost to patients in Thailand in exchange for the Thai government’s agreement not to issue a compulsory license on Novartis’ patent. Glivec® (imatinib), which is sold as Gleevac® (imatinib mesylate) in the U.S.,…
-
By Michael A. Einhorn, Ph.D. — [Ed. – Dr. Einhorn (at right) is an Academic Affiliate of Campos and Stratis IP and an Adjunct Professor at the Rothman Institute of Entrepreneurship at Fairleigh Dickinson University in Madison, New Jersey. The following article originally appeared in the Intellectual Property Newsletter of the American Bar…
-
By Donald Zuhn — The U.S. Patent and Trademark Office announced today that Nathaniel Wienecke (at right), Assistant Secretary for Legislative and Intergovernmental Affairs of the U.S. Department of Commerce, has addressed a letter to Senator Patrick Leahy, Chairman of the Senate Judiciary Committee, expressing the Bush Administration’s views on the Senate patent…
Patent Docs 